| olafertinib (CK-101) / Sun Pharma |
CTR20200563: Phase III clinical study of RX518 as first-line treatment for patients with non-small cell lung cancer |
|
|
| Recruiting | 3 | 480 | China | olafertinib (CK-101) - Fortress, gefitinib - Generic mfg. | Suzhou Runxin Biotechnology Co., Ltd. | Advanced Non-small Cell Lung Cancer;Oncology | | | | |
CTR20182402: Phase I clinical study of RX518 in patients with advanced non-small cell lung cancer |
|
|
| Completed | 1 | 50 | China | olafertinib (CK-101) - Fortress | Suzhou Runxin Biotechnology Co., Ltd. | Advanced Non-small Cell Lung Cancer;Oncology | | | | |
| RX208 / Suzhou NeuPharma |
NCT05092802: The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line Treatment |
|
|
| Recruiting | 2 | 40 | RoW | HLX208 | Shanghai Henlius Biotech | Brain Tumor, Primary | 05/23 | 05/24 | | |
NCT05065398: A Phase II Clinical Trial to Evaluate HLX208 in Advanced Non-small Cell Lung Cancer Patients With BRAF V600 Mutation |
|
|
| Recruiting | 2 | 20 | RoW | HLX208 | Shanghai Henlius Biotech | NSCLC | 06/23 | 12/23 | | |
NCT05114603: A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation |
|
|
| Recruiting | 2 | 30 | RoW | HLX208 | Shanghai Henlius Biotech | Advanced Melanoma | 08/23 | 08/24 | | |
NCT05127759: The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation |
|
|
| Active, not recruiting | 2 | 25 | RoW | HLX208, BRAF V600E inhibitor | Shanghai Henlius Biotech | Metastatic Colorectal Cancer, mCRC | 01/24 | 06/25 | | |
NCT04984369: The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment |
|
|
| Active, not recruiting | 2 | 50 | RoW | HLX208, BRAF V600E inhibitor, Cetuximab Injection [Erbitux] | Shanghai Henlius Biotech | CRC | 06/24 | 01/25 | | |
NCT05092815: The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation |
|
|
| Active, not recruiting | 2 | 25 | RoW | HLX208, BRAF V600E inhibitor | Shanghai Henlius Biotech | Langerhans Cell Histiocytosis, Erdheim-Chester Disease, LCH, ECD | 06/24 | 10/24 | | |
NCT05528406: A Phase II Clinical Trial to Evaluate HLX208 in Advanced Solid Tumor Patients With BRAF V600 Mutation |
|
|
| Not yet recruiting | 2 | 30 | NA | HLX208 | Shanghai Henlius Biotech | Solid Tumor | 10/24 | 06/25 | | |
NCT05102292: The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation |
|
|
| Active, not recruiting | 1/2 | 25 | RoW | HLX208, BRAF V600E inhibitor | Shanghai Henlius Biotech | Anaplastic Thyroid Cancer, ATC | 06/24 | 12/24 | | |
NCT05641493: A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation |
|
|
| Recruiting | 1/2 | 49 | RoW | HLX208+HLX10 | Shanghai Henlius Biotech | Non Small Cell Lung Cancer | 03/25 | 02/26 | | |
NCT05902728: Study on Food Influence and Drug-drug Interaction of HLX208 Tablets in Chinese Healthy Subjects |
|
|
| Completed | 1 | 20 | RoW | HLX208, Itraconazole 200 mg, Rifampicin | Shanghai Henlius Biotech | NSCLC | 12/23 | 12/23 | | |
NCT05841940: Mass Balance Study of [14C]HLX208 in China Healthy Subjects |
|
|
| Completed | 1 | 6 | RoW | [14C]HLX208 | Shanghai Henlius Biotech | Mass Balance Study in Healthy Subjects | 07/23 | 12/23 | | |
NCT04965220: HLX208 (BRAF V600E Inhibitor) in Combination With Trametinib in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 220 | RoW | HLX 208, trametinib | Shanghai Henlius Biotech | Solid Tumor | 06/24 | 06/25 | | |
| RX108 / Suzhou NeuPharma |
ChiCTR2100052066: Safety and efficacy of RX108 delivered via drug eluting beads transarterial chemoembolization (DEB-TACE) in patients with primary hepatocellular carcinoma |
|
|
| Recruiting | 2 | 20 | | RX108 delivered via drug eluting beads transarterial chemoembolization (DEB-TACE) | Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center, Suzhou NeuPharma Co., Ltd. | Primary hepatocellular carcinoma | | | | |
ACTRN12623000307606: Phase I study to evaluate Safety and Tolerability of RX108-A Tablets in Patients with advanced Cancer |
|
|
| Recruiting | 1 | 20 | | | NeuPharma Pty Ltd, NeuPharma Pty Ltd | Locally Advanced or Metastatic Solid Tumors | | | | |
NCT03646071: A Study of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 80 | US | RX108 | NeuPharma, Inc. | Locally Advanced Solid Tumors, Metastatic Solid Tumors | 08/23 | 12/23 | | |
ACTRN12616000008426: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RX108 in Patients with Advanced or Metastatic Solid Tumours. |
|
|
| Recruiting | N/A | 35 | | | Suzhou NeuPharma Co., Ltd., Suzhou NeuPharma Co., Ltd. | Advanced or Metastatic Solid Tumours | | | | |
